KYMRKymera Therapeutics, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+11% of shares).
Choppy, but holding above its 200-day average. Price is +22% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How KYMR is trading
Kymera Therapeutics, Inc. is +129% over the past year while the S&P 500 is +18%: 110 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +22%
vs 200-day average · a clear uptrend
- RSI (14)
- 42
RSI (14) · neutral
- Below its 52-week high
- 12%
Below its 52-week high
Details›
- Last close2026-10-09
- $112.32
- 1 monthS&P 500 +2.7%
- −4.0%
- 1 yearS&P 500 +18%
- +129%
- 5 yearsS&P 500 +88%
- +78%
- vs 50-day average$114.46
- −1.9%
- 52-week high
- $127.24
- 52-week low
- $50.87
- Annualised volatility
- 69%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$174M
| Year | Return |
|---|---|
| 2026 (year to date) | +44% |
| 2025 | +93% |
| 2024 | +58% |
| 2023 | +2.0% |
| 2022 | −61% |
| 2021 | +2.4% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 2 of 6 | +6.1% |
| Feb | 6 | 2 of 6 | −1.5% |
| Mar | 6 | 1 of 6 | −7.6% |
| Apr | 6 | 3 of 6 | +0.65% |
| May | 6 | 2 of 6 | −12% |
| Jun | 6 | 4 of 6 | +17% |
| Jul | 6 | 4 of 6 | +13% |
| Aug | 6 | 4 of 6 | +4.9% |
| Sep | 7 | 2 of 7 | −3.6% |
| Oct | 7 | 5 of 7 | +6.0% |
| Nov | 6 | 4 of 6 | +18% |
| Dec | 6 | 4 of 6 | +9.4% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.